234 related articles for article (PubMed ID: 36987694)
1. The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands.
van Schoonhoven AV; Schöttler MH; Serné EH; Schrömbges PPG; Postma MJ; Boersma C
J Med Econ; 2023; 26(1):547-553. PubMed ID: 36987694
[TBL] [Abstract][Full Text] [Related]
2. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.
Morton JI; Marquina C; Shaw JE; Liew D; Polkinghorne KR; Ademi Z; Magliano DJ
Diabetologia; 2023 Apr; 66(4):642-656. PubMed ID: 36404375
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Nat Rev Endocrinol; 2020 Oct; 16(10):556-577. PubMed ID: 32855502
[TBL] [Abstract][Full Text] [Related]
4. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature review.
Peng ZY; Yang CT; Ou HT; Kuo S
Diabetes Obes Metab; 2022 Jul; 24(7):1328-1337. PubMed ID: 35373898
[TBL] [Abstract][Full Text] [Related]
6. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Elsisi GH; Anwar MM; Khattab M; Elebrashy I; Wafa A; Elhadad H; Awad M; Carapinha JL
J Med Econ; 2020 Aug; 23(8):908-914. PubMed ID: 32364032
[No Abstract] [Full Text] [Related]
7. Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.
de Pouvourville G; Rossignol P; Boussahoua M; Chevalier J; Gabb PD; Poulnais R; Verboux D; Rao N; Sörstadius E; Garcia Sanchez JJ
Adv Ther; 2023 Sep; 40(9):3751-3769. PubMed ID: 37341914
[TBL] [Abstract][Full Text] [Related]
8. Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.
McEwan P; Hafner M; Jha V; Correa-Rotter R; Chernin G; De Nicola L; Villanueva R; Wheeler DC; Barone S; Nolan S; Garcia Sanchez JJ
J Med Econ; 2023; 26(1):1407-1416. PubMed ID: 37807895
[TBL] [Abstract][Full Text] [Related]
9. Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.
Kovesdy C; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Fried L
BMC Med; 2022 Jan; 20(1):2. PubMed ID: 35000594
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease.
Scheen AJ
Clin Pharmacokinet; 2020 Aug; 59(8):981-994. PubMed ID: 32201911
[TBL] [Abstract][Full Text] [Related]
11. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
Qiu M; Ding LL; Zhang M; Lin JH; Gu JS; Zhou X; Tang YX; Wei XB; Liu SY
Pharmacol Res; 2020 Nov; 161():105175. PubMed ID: 32860942
[TBL] [Abstract][Full Text] [Related]
13. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
14. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
[TBL] [Abstract][Full Text] [Related]
15. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines.
Ciardullo S; Trevisan R; Perseghin G
Pharmacol Res; 2021 Apr; 166():105530. PubMed ID: 33675963
[TBL] [Abstract][Full Text] [Related]
17. Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes.
Park S; Jeong HE; Bea S; Yu OHY; Cho YM; You SC; Man KKC; Shin JY
Diabetes Obes Metab; 2023 Nov; 25(11):3248-3258. PubMed ID: 37503763
[TBL] [Abstract][Full Text] [Related]
18. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
Weir MR; McCullough PA; Buse JB; Anderson J
Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
20. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
